Aricept and Cytolytic hepatitis - a phase IV clinical study of FDA data

Summary:

Cytolytic hepatitis is reported as a side effect among people who take Aricept (donepezil hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Nexium, and have Osteitis.

The phase IV clinical study analyzes which people have Cytolytic hepatitis when taking Aricept. It is created by eHealthMe based on reports of 23,732 people who have side effects when taking Aricept from the FDA, and is updated regularly.

What is Aricept?

Aricept has active ingredients of donepezil hydrochloride. It is often used in alzheimer's disease. eHealthMe is studying from 24,756 Aricept users. Check the latest studies of Aricept.

What is Cytolytic hepatitis?

Cytolytic hepatitis (dissolution or destruction of a liver cell) is found to be associated with 454 drugs and 910 conditions by eHealthMe. Check the latest studies of Cytolytic hepatitis.

On Jul, 11, 2026

23,732 people reported to have side effects when taking Aricept.
Among them, 30 people (0.13%) have Cytolytic hepatitis.

Could Aricept cause Cytolytic hepatitis?

Among these 30 people:

How long have people been on Aricept when they have Cytolytic hepatitis? *

What is the gender of people who have Cytolytic hepatitis when taking Aricept? *

female: 82.14 %
male: 17.86 %

What is the age of people who have Cytolytic hepatitis when taking Aricept? *

What are other drugs people take besides Aricept? *

What are other side effects people have besides Cytolytic hepatitis? *

Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 4 people, 13.33%
Gallstones (stone formation by bile component): 4 people, 13.33%
Weakness: 3 people, 10.00%
Rashes (redness): 3 people, 10.00%
Nausea And Vomiting: 2 people, 6.67%
Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 2 people, 6.67%
Hepatitis Cholestatic (flow of bile from the liver is slowed or blocked): 2 people, 6.67%
Oxygen Saturation Decreased: 2 people, 6.67%
Dehydration (dryness resulting from the removal of water): 2 people, 6.67%
Dyspnea (difficult or laboured breathing): 2 people, 6.67%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 10.00%
Osteitis (a general term for inflammation of bone): 3 people, 10.00%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 2 people, 6.67%
Breast Cancer: 2 people, 6.67%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 2 people, 6.67%
Ill-Defined Disorder: 2 people, 6.67%
Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 2 people, 6.67%
Urinary Tract Infection: 1 person, 3.33%
High Blood Pressure: 1 person, 3.33%
High Blood Cholesterol: 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Aricept and have Cytolytic hepatitis?

- Check whether Cytolytic hepatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aricept:

Aricept (24,756 reports)

Browse all side effects of Aricept:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cytolytic hepatitis:

Cytolytic hepatitis (454 drugs)

Browse all the conditions that are associated with Cytolytic hepatitis:

Cytolytic hepatitis (910 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on donepezil hydrochloride (the active ingredients of Aricept) and Aricept (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.